Alnylam Pharmace. buy Biotechhunter
Summary
This prediction ended on 13.05.20 with a price of €129.92. With a performance of -1.84%, the BUY prediction by Biotechhunter finished with a loss. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -1.894% | -1.894% | 15.233% | 51.038% |
| iShares Core DAX® | -4,93 % | -11,98 % | -3,67 % | 45,80 % |
| iShares Nasdaq 100 | -2,63 % | -2,22 % | 14,64 % | 78,69 % |
| iShares Nikkei 225® | -4,73 % | -10,90 % | 19,74 % | 45,87 % |
| iShares S&P 500 | -2,54 % | -3,54 % | 9,34 % | 58,52 % |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.


